DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,038 filers reported holding DANAHER CORPORATION in Q4 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,647,611 | +2.6% | 10,597 | +2.5% | 0.39% | +1.0% |
Q1 2024 | $2,580,558 | +1.8% | 10,334 | -5.7% | 0.39% | -5.1% |
Q4 2023 | $2,534,043 | +49.5% | 10,954 | +60.3% | 0.41% | +35.1% |
Q3 2023 | $1,695,490 | +20.9% | 6,834 | +16.9% | 0.30% | +25.3% |
Q2 2023 | $1,402,560 | -12.3% | 5,844 | -7.9% | 0.24% | -16.3% |
Q1 2023 | $1,598,887 | +14.2% | 6,344 | +20.2% | 0.29% | +9.9% |
Q4 2022 | $1,400,269 | +15.4% | 5,276 | +12.4% | 0.26% | +9.2% |
Q3 2022 | $1,213,000 | +4.9% | 4,696 | +3.0% | 0.24% | +10.1% |
Q2 2022 | $1,156,000 | -4.6% | 4,561 | +10.4% | 0.22% | +11.2% |
Q1 2022 | $1,212,000 | +20.8% | 4,133 | +13.0% | 0.20% | +17.4% |
Q4 2021 | $1,003,000 | +84.7% | 3,658 | +105.2% | 0.17% | +79.6% |
Q3 2021 | $543,000 | +39.6% | 1,783 | +23.1% | 0.09% | +36.8% |
Q2 2021 | $389,000 | +39.4% | 1,448 | +17.0% | 0.07% | +28.3% |
Q1 2021 | $279,000 | +220.7% | 1,238 | +216.6% | 0.05% | +194.4% |
Q4 2020 | $87,000 | +3.6% | 391 | 0.0% | 0.02% | -5.3% |
Q3 2020 | $84,000 | +21.7% | 391 | 0.0% | 0.02% | +11.8% |
Q2 2020 | $69,000 | +27.8% | 391 | 0.0% | 0.02% | +6.2% |
Q1 2020 | $54,000 | +14.9% | 391 | +27.8% | 0.02% | +45.5% |
Q4 2019 | $47,000 | +6.8% | 306 | 0.0% | 0.01% | 0.0% |
Q3 2019 | $44,000 | +51.7% | 306 | +48.5% | 0.01% | +37.5% |
Q2 2019 | $29,000 | +7.4% | 206 | 0.0% | 0.01% | 0.0% |
Q1 2019 | $27,000 | +28.6% | 206 | 0.0% | 0.01% | +14.3% |
Q4 2018 | $21,000 | -46.2% | 206 | -42.1% | 0.01% | -36.4% |
Q3 2018 | $39,000 | +11.4% | 356 | 0.0% | 0.01% | 0.0% |
Q2 2018 | $35,000 | 0.0% | 356 | 0.0% | 0.01% | 0.0% |
Q1 2018 | $35,000 | +6.1% | 356 | 0.0% | 0.01% | +10.0% |
Q4 2017 | $33,000 | +6.5% | 356 | 0.0% | 0.01% | 0.0% |
Q3 2017 | $31,000 | +3.3% | 356 | 0.0% | 0.01% | -9.1% |
Q2 2017 | $30,000 | 0.0% | 356 | 0.0% | 0.01% | 0.0% |
Q1 2017 | $30,000 | +7.1% | 356 | 0.0% | 0.01% | 0.0% |
Q4 2016 | $28,000 | 0.0% | 356 | 0.0% | 0.01% | -8.3% |
Q3 2016 | $28,000 | -22.2% | 356 | 0.0% | 0.01% | -25.0% |
Q2 2016 | $36,000 | +44.0% | 356 | +35.4% | 0.02% | +23.1% |
Q1 2016 | $25,000 | +78.6% | 263 | +75.3% | 0.01% | +85.7% |
Q4 2015 | $14,000 | +7.7% | 150 | 0.0% | 0.01% | 0.0% |
Q3 2015 | $13,000 | 0.0% | 150 | 0.0% | 0.01% | 0.0% |
Q2 2015 | $13,000 | 0.0% | 150 | 0.0% | 0.01% | 0.0% |
Q1 2015 | $13,000 | 0.0% | 150 | 0.0% | 0.01% | 0.0% |
Q4 2014 | $13,000 | +18.2% | 150 | 0.0% | 0.01% | +16.7% |
Q3 2014 | $11,000 | 0.0% | 150 | 0.0% | 0.01% | 0.0% |
Q2 2014 | $11,000 | 0.0% | 150 | 0.0% | 0.01% | -14.3% |
Q1 2014 | $11,000 | +83.3% | 150 | 0.0% | 0.01% | +75.0% |
Q4 2013 | $6,000 | – | 150 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |